Barclays PLC Inmune Bio, Inc. Transaction History
Barclays PLC
- $854 Billion
- Q3 2025
A detailed history of Barclays PLC transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 30,006 shares of INMB stock, worth $43,508. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,006
Previous 37,986
21.01%
Holding current value
$43,508
Previous $88,000
29.55%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding INMB
# of Institutions
84Shares Held
5.36MCall Options Held
310KPut Options Held
371K-
Vanguard Group Inc Valley Forge, PA876KShares$1.27 Million0.0% of portfolio
-
Black Rock Inc. New York, NY813KShares$1.18 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$864,73945.87% of portfolio
-
Geode Capital Management, LLC Boston, MA469KShares$680,6880.0% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL369KShares$535,6850.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $26M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...